This publication summarises the clinical benefits, safety and tolerability of faricimab (Vabysmo®), a bispecific antibody targeting vascular endothelial growth factor (VEGF)-A and angiopoietin (Ang)-2, for the treatment of diabetic macular oedema (DMO). Faricimab is now funded in New Zealand for DMO and neovascular age-related macular degeneration, for patients who meet Special Authority Criteria.
Please login below to download this issue (PDF)